## Mei-Ling Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2807240/publications.pdf

Version: 2024-02-01

393982 414034 1,200 41 19 32 citations h-index g-index papers 42 42 42 1354 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Mitochondrial dysfunction caused by outer membrane vesicles from Gram-negative bacteria activates intrinsic apoptosis and inflammation. Nature Microbiology, 2020, 5, 1418-1427.	5.9	105
2	An "Unlikely―Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. ACS Infectious Diseases, 2016, 2, 478-488.	1.8	80
3	Fitness cost of mcr-1-mediated polymyxin resistance in Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2018, 73, 1604-1610.	1.3	68
4	Polymyxin-Induced Lipid A Deacylation in <i>Pseudomonas aeruginosa</i> Penetration and Confers High-Level Resistance. ACS Chemical Biology, 2018, 13, 121-130.	1.6	59
5	Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	58
6	Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. Cell Chemical Biology, 2018, 25, 380-391.e5.	2.5	57
7	A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nature Communications, 2022, 13, 1625.	5.8	53
8	Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa. MSystems, 2019, 4, .	1.7	52
9	Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii. Scientific Reports, 2016, 6, 22287.	1.6	49
10	From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs―Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Microbial Drug Resistance, 2017, 23, 640-650.	0.9	45
11	Genome-scale metabolic modeling of responses to polymyxins in (i) Pseudomonas aeruginosa ( $i$ ). GigaScience, 2018, 7, .	3.3	44
12	Emergence of High-Level Colistin Resistance in an Acinetobacter baumannii Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	36
13	Polymyxins Bind to the Cell Surface of Unculturable <i>Acinetobacter baumannii</i> and Cause Unique Dependent Resistance. Advanced Science, 2020, 7, 2000704.	5.6	31
14	A polytherapy based approach to combat antimicrobial resistance using cubosomes. Nature Communications, 2022, 13, 343.	5.8	31
15	Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	28
16	Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of <i>Paenibacillus polymyxa</i> ATCC 10401. Journal of Natural Products, 2017, 80, 1264-1274.	1.5	27
17	Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. ACS Infectious Diseases, 2017, 3, 606-619.	1.8	25
18	Molecular dynamics simulations informed by membrane lipidomics reveal the structure–interaction relationship of polymyxins with the lipid A-based outer membrane of ⟨i⟩Acinetobacter baumannii⟨ i⟩. Journal of Antimicrobial Chemotherapy, 2020, 75, 3534-3543.	1.3	25

#	Article	IF	Citations
19	Lipidomic Analysis of the Outer Membrane Vesicles from Paired Polymyxin-Susceptible and -Resistant Klebsiella pneumoniae Clinical Isolates. International Journal of Molecular Sciences, 2018, 19, 2356.	1.8	23
20	Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Pharmacology, 2019, 10, 754.	1.6	21
21	Plasma Protein Binding Structure–Activity Relationships Related to the N-Terminus of Daptomycin. ACS Infectious Diseases, 2017, 3, 249-258.	1.8	20
22	Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Microbiology, 2018, 9, 2776.	1.5	20
23	Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa. Computational and Structural Biotechnology Journal, 2018, 16, 587-599.	1.9	19
24	Outer Membranes of Polymyxin-Resistant <i>Acinetobacter baumannii</i> with Phosphoethanolamine-Modified Lipid A and Lipopolysaccharide Loss Display Different Atomic-Scale Interactions with Polymyxins. ACS Infectious Diseases, 2020, 6, 2698-2708.	1.8	19
25	Comparative analysis of phosphoethanolamine transferases involved in polymyxin resistance across 10 clinically relevant Gram-negative bacteria. International Journal of Antimicrobial Agents, 2018, 51, 586-593.	1.1	18
26	Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa. Frontiers in Pharmacology, 2019, 10, 1146.	1.6	17
27	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
28	Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii. Biochemical Pharmacology, 2021, 184, 114400.	2.0	16
29	Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	15
30	A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant <i>Klebsiella pneumoniae</i> Strains. ACS Infectious Diseases, 2018, 4, 1692-1704.	1.8	15
31	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR <i>Klebsiella pneumoniae</i> clinical isolates from the same patients before and after colistin treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 2852-2863.	1.3	14
32	A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles. Journal of Biomedical Nanotechnology, 2017, 13, 447-457.	0.5	12
33	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
34	Polymyxin resistance in Klebsiella pneumoniae: multifaceted mechanisms utilized in the presence and absence of the plasmid-encoded phosphoethanolamine transferase gene mcr-1. Journal of Antimicrobial Chemotherapy, 2019, 74, 3190-3198.	1.3	12
35	Phytantriol-Based Cubosome Formulation as an Antimicrobial against Lipopolysaccharide-Deficient Gram-Negative Bacteria. ACS Applied Materials & Samp; Interfaces, 2020, 12, 44485-44498.	4.0	12
36	Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination. Computational and Structural Biotechnology Journal, 2022, 20, 485-495.	1.9	12

#	Article	IF	CITATION
37	Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
38	Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli. Frontiers in Microbiology, 2020, 11, 588658.	1.5	7
39	Correlative proteomics identify the key roles of stress tolerance strategies in Acinetobacter baumannii in response to polymyxin and human macrophages. PLoS Pathogens, 2022, 18, e1010308.	2.1	6
40	An Intelligent Strategy with All-Atom Molecular Dynamics Simulations for the Design of Lipopeptides against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . Journal of Medicinal Chemistry, 2022, 65, 10001-10013.	2.9	6
41	Polymyxin-Induced Metabolic Perturbations in Human Lung Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, e0083521.	1.4	3